Compare SELF & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | SCLX |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.0M | 52.9M |
| IPO Year | 1997 | N/A |
| Metric | SELF | SCLX |
|---|---|---|
| Price | $5.33 | $5.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 27.5K | ★ 34.1K |
| Earning Date | 05-08-2026 | 04-10-2026 |
| Dividend Yield | ★ 5.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $12,705,245.00 | N/A |
| Revenue This Year | $3.04 | $122.52 |
| Revenue Next Year | $3.47 | $186.30 |
| P/E Ratio | $29.78 | ★ N/A |
| Revenue Growth | ★ 1.40 | N/A |
| 52 Week Low | $4.73 | $3.60 |
| 52 Week High | $5.83 | $34.27 |
| Indicator | SELF | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | 35.17 |
| Support Level | $5.12 | $4.56 |
| Resistance Level | $5.31 | $7.76 |
| Average True Range (ATR) | 0.12 | 0.66 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 81.82 | 53.09 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.